Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid entities : Abcellera biologics inc save search
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
Published: 2021-12-03 (Crawled : 22:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: 3.41%
H: 0.0%
C: 0.0%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
covid therapy authorized antibody merge
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
Published: 2021-11-02 (Crawled : 23:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: -0.41%
H: 5.54%
C: 4.54%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
covid treatment
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
Published: 2021-09-21 (Crawled : 19:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: -0.58%
H: 3.16%
C: 2.68%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 2.04%
H: 0.72%
C: -0.81%
covid treatment
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: -0.11%
H: 5.8%
C: 5.38%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.15%
H: 0.26%
C: -1.3%
covid fda merge authorized emergency use authorization
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: -0.65%
H: 10.38%
C: 8.4%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.87%
H: 1.36%
C: 0.36%
covid clinical trials antibody trial covid-19
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
Published: 2021-03-10 (Crawled : 17:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: 1.27%
H: 5.99%
C: 3.83%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.38%
H: 0.56%
C: -0.69%
covid phase 3 trial
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
Published: 2021-03-05 (Crawled : 00:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: 1.53%
H: 4.02%
C: -6.23%
covid ema
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 07:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: 12.77%
H: 0.06%
C: -11.34%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda antibody merge authorized covid-19 emergency use authorization
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
Published: 2021-01-26 (Crawled : 13:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: 1.02%
H: 1.36%
C: -3.08%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.09%
H: 0.32%
C: 0.08%
covid antibody risk
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents
Published: 2021-01-21 (Crawled : 23:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: 1.66%
H: 5.08%
C: 3.88%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 1.21%
H: 0.5%
C: -0.66%
covid antibody risk
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
Published: 2020-12-21 (Crawled : 17:00) - biospace.com/
ABCL | $3.8 -2.56% 290K
|
|
| O: -1.46%
H: 1.01%
C: -6.6%
covid antibody covid-19
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
SGBX | $0.26 80.43% 54M
|
Producer Manufacturing
LICN | $1.0 78.57% 3.3M
|
CSSE 4 | $0.2656 74.39% 9.7M
|
Consumer Services
BRFH 4 | $1.89 71.82% 32M
|
Manufacturing
ACON | $0.49 70.14% 24M
|
n/a
BOF | $1.95 66.67% 920K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.13 56.5% 500K
|
Technology Services
PCSA | $2.28 40.74% 37M
|
Producer Manufacturing
EVA | $0.626 39.14% 2.3M
|
Process Industries
Your saved searches
Save your searches and get alerts when important news are released.